BEMCENTINIB PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRUTAL IMMUNOLOGY 2021
Bergen, Norway, 26 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a poster presentation on pre-clinical COVID-19 data has been accepted for presentation at Virtual Immunology 2021, taking place from 10-15 May 2021. Virtual Immunology 2021 is the 104[th] annual conference of the American Association of Immunologists. The presentation illustrates findings from a pre-clinical study conducted by BerGenBio’s scientific collaborator Professor Wendy